The FTC report said the companies responsible for controlling spending on drugs were sometimes steering patients toward more expensive medicines.

The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged anticompetitive practices that boosted profits while

The FTC said CVS Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx profit at the expense of patients forced to pay more for insulin.